Shares

Galafold Oral Chaperone Therapy Reimbursed in Canada

The Canadian Drug Expert Committee (CDEC) and INESSS (Quebec) have recommended in favour of reimbursement of Galafold for long-term treatment of adults with a confirmed diagnosis of Fabry Disease and who have an amenable mutation.  Funding is now available in all provinces & territories throughout Canada for amenable patients through exceptional access and/or special drug programs that meet the guidelines of Canadian Fabry Disease Treatment eligibility.  For more information please follow-up with your Fabry physician.

For more information on Galafold or Amicus Therapeutics, Inc please visit https://www.amicusrx.com/

Close

Contact Us

748 Kelly St
Thunder Bay ON P7E 2A1
Canada

If have any questions or would like to get involved, please fill in the form below.

Subscribe error, please review your email address.

Close

You're now subscribed, thank you!

Close

There was a problem with your submission. Please check the field(s) with red label below.

Close

Your message has been sent. We'll get back to you soon!

Close